Esperion Therapeutics (ESPR) Notes Payables (2024 - 2025)

Esperion Therapeutics (ESPR) posted Notes Payables of $54.9 million for Q3 2025, little changed on a QoQ basis from $54.8 million in Q2 2025.

Esperion Therapeutics (ESPR) Notes Payables (2024 - 2025) Analysis & Trends

Esperion Therapeutics' Notes Payables history runs 2 years deep, the most recent figure standing at $54.9 million for Q3 2025.

Quarterly Notes Payables changed N/A year-over-year to $54.9 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $54.9 million (changed N/A YoY) and the FY2024 annual result came in at $54.6 million, changed N/A from the prior year.
Notes Payables was $54.9 million for Q3 2025 at Esperion Therapeutics, roughly flat from $54.8 million in the prior quarter.
Across five years, Notes Payables topped out at $54.9 million in Q3 2025 and bottomed at $54.6 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn
10	Esperion Therapeutics	799.30 Mn	643.14 Mn	45.53 Mn

Download Data